2 results match your criteria: "Institute for Pharmacology and Preclinical Drug Safety (IPAS)[Affiliation]"
Life Sci
April 2013
Nycomed: A Takeda Company, Institute for Pharmacology and Preclinical Drug Safety (IPAS), Haidkrugsweg 1, 22885 Barsbuettel, Germany.
Aims: Although acute dextran sodium sulphate (DSS)-induced colitis in mice is frequently used as a preclinical model for testing drugs involved in inflammatory bowel disease (IBD), only limited data is available that compares the efficacy of established drug treatments and combinations employed in IBD. We have therefore compared the efficacy of aminosalicylates (mesalazine, olsalazine), corticosteroids (budesonide), thiopurines (6-thioguanine (6-TG)) and cyclosporine A (CsA) and combinations thereof as well as the EP4 agonist AGN205203 in the acute DSS-colitis model.
Main Methods: Female BALB/c mice were challenged with 4% DSS in drinking water for 7 days to induce colitis and treated daily with different drugs/combinations orally.
Toxicol Pathol
October 2013
Institute for Pharmacology and Preclinical Drug Safety (IPAS), Nycomed GmbH (Nycomed: A Takeda Company), Barsbüttel, Germany.
Testicular tubular dilatation and degeneration and epididymal sperm granulomas were frequently seen in 4-week toxicity studies using different phosphodiesterase-4 (PDE4) inhibitors in Wistar rats, including the prototypic PDE4 inhibitor BYK169171. To investigate the pathogenesis of testicular and epididymal lesions, a time course study with BYK169171 was conducted with sequential necropsies after 7, 14, 21, and 28 days of treatment. After 7 days, a dilatation of efferent ducts and of the initial segment of the epididymis and a subacute interstitial inflammation were seen followed by a diffuse dilatation of seminiferous tubules in the testis.
View Article and Find Full Text PDF